GEN Exclusives

More »

GEN News Highlights

More »
May 11, 2007

Bristol-Myers Squibb Adopts Asterand’s Drug Discovery Services for Three More Years

  • Asterand entered into a partnership with Bristol-Myers Squibb for access to Asterand's products and services for up to three years. The agreement will focus on access to Asterand's PhaseZERO® drug discovery services and Asterand's XpressBANK™ of human tissue and clinical samples for the validation of early drug targets and support for compound optimization.

    Asterand says its human tissue-based approach through PhaseZERO Services and XpressBANK Samples can help assist in the early identification of possible adverse events in humans and thus may help reduce the high attrition rates and costs associated with drug discovery and development.

    Under this extended collaboration, Asterand will continue to undertake a range of PhaseZERO studies for Bristol-Myers Squibb in the areas of compound profiling and target validation. Likewise, Bristol-Myers Squibb will be granted access to Asterand's XpressBANK of human tissue, bio-fluid, and cell lines and may also utilize Asterand's ProCURE custom clinical sample collection service.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »